Atriva

Atriva Therapeutics stands for the next generation of antiviral therapies. MEK Inhibitors have high potential as truly efficacious and safe antiviral drugs to address the urgent need e.g. for a novel, broadly active influenza therapy.

Press releases

HTGF News Atriva Therapeutics

HTGF portfolio company: EIB backs Atriva Therapeutics with €24 million for the development of a potential COVID-19 treatment European Investment Bank and Atriva Therapeutics sign financing agreement of €24 million for the research, development and clinical testing of the…
Read

HTGF Series Atriva Therapeutics

Atriva announces closing of € 8.6 million ($ 10.2 million) oversubscribed convertible loan Round led by existing investors Meneldor and High-Tech GründerfondsProceeds to be used to start Phase II study with ATR-002 in moderate to severe COVID-19 and clinical development…
Read

Atriva reaches a development milestone and receives an additional tranche of running seed financing to develop its influenza therapeutic to clinical stage

The next generation of Antiviral Therapies: Co-Led by Stichting Participatie Atriva and High-Tech Gründerfonds (HTGF), Atriva Therapeutics GmbH has received a second tranche of its running seed financing in total of € 3 Mn from Dutch, German and Canadian investors, after lead compound ATR-002 (Atriva’s antiviral…
Read

Info & Contact

Dr. Rainer Lichtenberger, CEO
Web:
www.atriva-therapeutics.com

Address

Atriva Therapeutics GmbH
Eisenbahnstr. 1
72072 Tübingen

In portfolio

27. Dec 2016